Alluvi, known as BI 4744, offers a significant advance in weight management treatment. This dual agonist targeting both GLP-1 and GIP sites demonstrates impressive efficacy in research trials, arguably outperforming https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/